EGFR and triple-negative breast carcinoma: In addition, resistance to EGFR inhibition is reported to be caused by hepatocyte growth factor (HGF) secretion by fibroblasts in triple-negative breast cancer, which activates EGFR-MET crosstalk [353], while the co-culture of prostate cancer cell lines with cancer-associated fibroblasts (CAFs) can mediate resistance to the multityrosine kinase inhibitor sorafenib [354].